New vaccine targets group a strep in first human test
NCT ID NCT07616934
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new vaccine called VAX-A1 in 80 healthy adults aged 18-40. The vaccine aims to prevent infections caused by Group A Streptococcus bacteria, which can cause strep throat and more serious illnesses. The study focuses on safety and immune response, with participants receiving either a low, mid, or high dose of the vaccine or a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VAX-A1 vaccine
- What this could lead to
- If successful, this could lead to a vaccine that prevents Group A Strep infections, which can cause strep throat, scarlet fever, and serious complications like rheumatic fever.
- What could go wrong
- This is a very early Phase 1 trial with only 80 healthy adults. The main goal is safety, not yet proof that the vaccine works. Many vaccines fail in early testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROUP A STREPTOCOCCAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fusion Clinical Research
RECRUITINGAdelaide, South Australia, 5067, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.